MedTrace Logo

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

NCT02790944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-08-25

No results posted yet for this study

Summary

The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.

Conditions

Interventions

GENETIC

Multi-gene Next Generation Sequencing Panel

Participants will have genetic testing

Sponsors & Collaborators

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • HonorHealth Research Institute

    collaborator OTHER

  • Ambry Genetics

    lead INDUSTRY

Principal Investigators

  • Randall Brand, MD · University of Pittsburgh

  • Nadine Tung, MD · Beth Israel Deaconess

  • Erkut Borazanci, MD · HonorHealth Research Institute

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-04
Primary Completion
2020-08-15
Completion
2020-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02790944 on ClinicalTrials.gov